GLP-1 and incretin compared
Semaglutide vs tirzepatide
Semaglutide and tirzepatide as once-weekly injections, with the large trials that compared them.
Semaglutide acts on the GLP-1 receptor, and tirzepatide acts on both the GIP and GLP-1 receptors.1,2 The Ozempic label gives semaglutide's half-life as approximately 1 week, and the Mounjaro label gives tirzepatide's as approximately 5 days.1,2
In SURMOUNT-5, which compared the highest tolerated weekly doses (tirzepatide 10 or 15 mg, semaglutide 1.7 or 2.4 mg) in 751 adults with obesity and without type 2 diabetes, the weight change at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide.3 The trial was open-label and funded by Eli Lilly, which makes tirzepatide.3
| Fact | Semaglutide | Tirzepatide |
|---|---|---|
| What it is | A GLP-1 receptor agonist marketed by Novo Nordisk1 | A once weekly GIP and GLP-1 receptor agonist made by Eli Lilly and Company2 |
| How it comes | Ozempic pens of 0.68, 1.34 or 2.68 mg/mL, injected under the skin once weekly1 | Mounjaro pens and vials from 2.5 mg/0.5 mL to 15 mg/0.5 mL, injected under the skin once weekly2 |
| Half-life | ||
| Doses and results | ||
| Status | First approved in the US in 2017, as Ozempic; also approved as Wegovy1,9 | First approved in the US in 2022, as Mounjaro; also approved as Zepbound2,10 |
Contents6
Last reviewed . Sources are listed below.
How they differ
A second head-to-head trial, SURPASS-2, randomised 1879 adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg.4 Glycated hemoglobin fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide against 1.86 with semaglutide at 40 weeks.4 Eli Lilly funded it.4
The weight figures in the table for each drug come from separate placebo-controlled trials, STEP 1 funded by Novo Nordisk and SURMOUNT-1 supported by Eli Lilly, so they were not compared directly.5,6
Levels after one dose
Logged in Milligram
- Semaglutide: Too few people logged it to show a share.
- Tirzepatide: 5% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.
What is not known
In a boxed warning, the Ozempic and Mounjaro labels state that each drug causes thyroid C-cell tumors in rodents, that it is unknown whether it does in humans, and that it is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.1,2 The two large trials on this page that compared them, SURMOUNT-5 and SURPASS-2, were open-label; no double-blind comparison is cited here.3,4
References
- Novo Nordisk Pharmaceutical Industries, LP. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. US label (DailyMed), 2026. DailyMed label
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Journal article (PubMed), 2025. PMID 40353578
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Phase 3 randomised trial, 2021. PMID 34170647
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Journal article (PubMed), 2021. PMID 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. Phase 3 randomised trial, 2022. PMID 35658024
- European Medicines Agency. Ozempic: summary of product characteristics (EPAR product information). EU product information, 2026. ema.europa.eu
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Phase 1 study and preclinical paper, 2018. PMC6308032
- Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection and tablets. Prescribing information, Novo Nordisk. US label (DailyMed), 2026. DailyMed label
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing information, revised August 2026. US label (DailyMed), 2026. DailyMed label